aTyr Pharma Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

aTyr PharmaDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -24.6% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind rückläufig mit einer durchschnittlichen Rate von 6.8% pro Jahr.

Wichtige Informationen

-24.6%

Wachstumsrate der Gewinne

40.9%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	-6.8%
Eigenkapitalrendite	-98.0%
Netto-Marge	-27,155.7%
Letzte Ertragsaktualisierung	30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Oct 04

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

May 06

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Jan 04

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

Sep 29

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

Sep 13

aTyr Pharma gains with FDA Fast Track status for lead asset

Aug 11

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

May 10

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Jan 24

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Dec 28

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Sep 24

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Sep 23

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

May 22

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 25

Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?

Feb 09

aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan

Jan 14

ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study

Jan 04

aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study

Dec 21

aTyr Pharma (LIFE) Investor Presentation - Slideshow

Oct 31

Aufschlüsselung der Einnahmen und Ausgaben

Wie aTyr Pharma Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqCM:ATYR Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Sep 24	0	-64	13	0
30 Jun 24	1	-58	13	0
31 Mar 24	1	-54	13	0
31 Dec 23	0	-50	13	0
30 Sep 23	11	-43	13	0
30 Jun 23	10	-45	14	0
31 Mar 23	10	-45	14	0
31 Dec 22	10	-45	14	0
30 Sep 22	0	-46	13	0
30 Jun 22	0	-41	12	0
31 Mar 22	0	-39	12	0
31 Dec 21	0	-34	11	0
30 Sep 21	2	-30	10	0
30 Jun 21	2	-29	10	0
31 Mar 21	2	-25	9	0
31 Dec 20	10	-16	9	0
30 Sep 20	9	-17	9	0
30 Jun 20	9	-16	9	0
31 Mar 20	8	-16	9	0
31 Dec 19	0	-24	9	0
30 Sep 19	0	-24	9	0
30 Jun 19	0	-25	10	0
31 Mar 19	0	-30	11	-6
31 Dec 18	0	-35	12	0
30 Sep 18	0	-40	16	5
30 Jun 18	0	-44	17	12
31 Mar 18	0	-45	17	27
31 Dec 17	0	-48	17	0
30 Sep 17	0	-49	15	34
30 Jun 17	0	-52	14	37
31 Mar 17	0	-55	15	40
31 Dec 16	0	-58	15	43
30 Sep 16	0	-62	16	46
30 Jun 16	0	-59	16	44
31 Mar 16	0	-55	15	40
31 Dec 15	0	-48	13	33
30 Sep 15	0	-38	11	25
30 Jun 15	0	-33	9	21
31 Mar 15	0	-28	8	18
31 Dec 14	0	-25	7	17
30 Sep 14	0	-24	6	17

Qualität der Erträge: ATYR ist derzeit unrentabel.

Wachsende Gewinnspanne: ATYR ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: ATYR ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 24.6% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von ATYR verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: ATYR ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (16.6%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: ATYR hat eine negative Eigenkapitalrendite (-97.97%), da es derzeit unrentabel ist.

aTyr Pharma Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

aTyr Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

aTyr Pharma, Inc. to Report Q3, 2022 Results on Nov 10, 2022

aTyr Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

aTyr Pharma, Inc. to Report Q1, 2022 Results on May 09, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2020)

Recent updates

New minor risk - Financial position

New minor risk - Profitability

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

New minor risk - Share price stability

Independent Director recently bought US$185k worth of stock

aTyr Pharma, Inc. Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully

Independent Chairman of the Board recently bought US$88k worth of stock

Price target increased by 8.8% to US$24.60

aTyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

Consensus revenue estimates decrease by 85%, EPS upgraded

aTyr Pharma, Inc., Annual General Meeting, May 22, 2024

Consensus revenue estimates fall by 70%

New minor risk - Profitability

New major risk - Revenue size

Forecast to breakeven in 2026

aTyr Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

aTyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis

We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely

Consensus revenue estimates fall by 93%

Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect™? Study of Efzofitimod in Patients with Ssc-Ild

Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Atyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, Fvc and Patient Reported Outcomes

Consensus EPS estimates upgraded to US$0.90 loss

Price target increased by 17% to US$23.25

Consensus EPS estimates upgraded to US$1.03 loss

Independent Director recently bought US$450k worth of stock

Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation

Consensus revenue estimates fall by 25%

Price target increased by 8.9% to US$22.00

Consensus revenue estimates decrease by 25%

We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate

Consensus forecasts updated

Price target decreased to US$21.20

Insufficient new directors

aTyr Pharma, Inc. Announces Publication of Positive Data from Phase 1B/2A Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal Chest

aTyr Pharma, Inc. to Report Q3, 2022 Results on Nov 10, 2022

aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies

aTyr Pharma, Inc. Announces Dosing of First Patient in Pivotal Phase 3 Efzo-Fit™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

Consensus revenue estimates fall by 67%

aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease

aTyr Pharma, Inc. Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

aTyr Pharma gains with FDA Fast Track status for lead asset

aTyr Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Price target decreased to US$17.33

Atyr Pharma, Inc. Announces Phase 3 Study Evaluating the Efficacy and Safety of Its Lead Therapeutic Candidate, efzofitimod

Consensus revenue estimates fall by 33%

We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully

aTyr Pharma, Inc. to Report Q1, 2022 Results on May 09, 2022

Insufficient new directors

aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2020)

aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

aTyr Pharma, Inc. Announces Positive Data from Phase 1B/2A Clinical Trial Demonstrating Consistent Dose Response for Atyr1923 in Pulmonary Sarcoidosis

Price target increased to US$19.25

Consensus forecasts updated

Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?

Independent Director recently bought US$199k worth of stock

Consensus forecasts updated

Price target increased to US$17.67

aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Full year 2020 earnings released: US$1.77 loss per share (vs US$7.03 loss in FY 2019)

aTyr Pharma, Inc. to Report Q4, 2020 Results on Mar 23, 2021